ERBB2 and breast cancer: Scores from the 150 ctDNA-based signatures (adjusted by TF) were evaluated in paired plasma samples (i.e., baseline versus post-treatment after progressive disease) in 7 patients with advanced HR+/HER2- breast cancer treated with endocrine therapy and a CDK4/6 inhibitor (Fig. 3f).